Facts & Figures
Science for a better life - Medical Progress for the Benefit of the Patient
Facts and Figures at a glance
|Research expenses 2012||1,962 € million (2011: 1,948 € million)|
|Proportion of total Bayer group research expenses 2012||65,1%|
|Employees in Research & Development||7,500|
|Main research locations||Berlin and Wuppertal, Germany, Berkeley, USA, Bejing, CHina
Research activities 2012
In 2012 we invested €1,962 million (2011: €1,948 million) in research and development in the Pharmaceuticals and Consumer Health segments. This amounted to 65.1% of the Bayer Group’s entire research and development spending and was equivalent to 10.5% (2011: 11.3%) of HealthCare sales. At the end of 2012, some 7,500 employees of the HealthCare subgroup were working in research and development.
Research and development expenses in the Pharmaceuticals segment amounted to €1,566 million (2011: €1,556 million), or 14.5% (2011: 15.6%) of segment sales. Our research and development outlay underscores our focus on growth through innovation. Drug discovery in the Pharmaceuticals segment is concentrated in the areas of cardiology and oncology, along with gynecological treatments and hematology. Other areas of focus are the therapeutic areas of inflammation and ophthalmology. In addition, we are strengthening our established products through life-cycle management, an example being the development of innovative forms of administration for contraceptives.
We conducted clinical studies with several drug candidates from our research and development pipeline during 2012 to drive the development of new substances to treat diseases with a high unmet medical need. Following the completion of the required studies with a number of these drug candidates, we submitted applications to one or more regulatory agencies for approvals or approval extensions.
Four active ingredients / products have blockbuster potential. Of special importance is our anticoagulant Xarelto™ (rivaroxaban), which continues to be launched in more countries. In 2012 we filed for, and in some cases already received, marketing authorization in additional indications. In the area of oncology, regorafenib (registered in the United States under the trademark Stivarga™) is approved for the treatment of advanced colorectal cancer in some countries, and approval is pending in others.
At the end of 2012, we filed for marketing authorization for radium-223 dichloride (Alpharadin) for the therapy of bone metastases in prostate cancer patients. Other promising products being launched include Eylea™ (aflibercept) for the treatment of wet age-related macular degeneration.
Research activities and capacities are bundled in Germany at the sites in Berlin and Wuppertal, and in the United States in the Mission Bay neighborhood of San Francisco and at Berkeley, California. Work in Berlin and Wuppertal mainly focuses on the discovery, optimization and development of new active substances. Research is also carried out at these sites in the fields of drug metabolism, pharmaco kinetics, toxicology and clinical pharmacology. Our research and development activities in Mission Bay and Berkeley are concentrated on biologicals and hematology. We also operate an innovation center in Beijing, China.